World's Best Scientists 2026 revealed!
Alessandro D. Santin

Alessandro D. Santin

D-Index & Metrics

Medicine

D-Index
76
Citations
21701
World Ranking
18766
National Ranking
9351

Alessandro D. Santin publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Alessandro D. Santin sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 618 publications — 74th percentile

74% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Alessandro D. Santin D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Alessandro D. Santin sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 76 D-Index — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Alessandro D. Santin is affiliated with Yale University in the United States and has a substantial publication record primarily in the field of Medicine, with a particular focus on Oncology, Reproductive Medicine, and Obstetrics and Gynecology. Their research spans several key areas within cancer biology and treatment.

They have contributed extensively to multiple academic journals, frequently publishing in the following venues:

  • Gynecologic Oncology
  • Journal of Clinical Oncology
  • International Journal of Gynecological Cancer
  • Gynecologic Oncology Reports
  • SSRN Electronic Journal

Their research output covers major topics such as:

  • Ovarian cancer diagnosis and treatment
  • HER2/EGFR in Cancer Research
  • Endometrial and Cervical Cancer Treatments
  • Monoclonal and Polyclonal Antibodies Research
  • Uterine Myomas and Treatments
  • Sarcoma Diagnosis and Treatment
  • Cancer Immunotherapy and Biomarkers

Frequent collaborators in their work include:

  • Elena Ratner (78 coauthored works)
  • Stefania Bellone (66 coauthored works)
  • Masoud Azodi (52 coauthored works)
  • Gary Altwerger (52 coauthored works)
  • Gloria S. Huang (47 coauthored works)

Among notable recent publications, the following papers stand out:

  • "Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial" (2021, Annals of Oncology)
  • "Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis" (2020, Clinical Cancer Research)
  • "First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors" (2020, Journal of Clinical Oncology)
  • "Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)" (2020, Gynecologic Oncology)
  • "Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis" (2021, Cancer)

Their research integrates clinical trials and translational studies focusing on therapeutic strategies, including antibody-drug conjugates and immunotherapy approaches for gynecological cancers.

Best Publications

  • Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A Mayer;Linda T Vahdat;Sara M Tolaney

  • Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

    U.A. Matulonis;R. Shapira-Frommer;A.D. Santin;A.S. Lisyanskaya

  • The CA 125 gene: an extracellular superstructure dominated by repeat sequences.

    Timothy J. O’Brien;John B. Beard;Lowell J. Underwood;Richard A. Dennis

  • Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu

    Amanda N. Fader;Dana M. Roque;Eric Siegel;Natalia Buza

  • Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy

    Alessandro D. Santin;Fenghuang Zhan;Stefania Bellone;Michela Palmieri

  • Tumor-associated macrophages drive spheroid formation during early transcoelomic metastasis of ovarian cancer

    Mingzhu Yin;Xia Li;Shu Tan;Huanjiao Jenny Zhou

  • Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma.

    Siming Zhao;Murim Choi;John D. Overton;Stefania Bellone

  • Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy.

    Alessandro D. Santin;Fenghuang Zhan;Eliana Bignotti;Eric R. Siegel

  • Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes.

    Alessandro D. Santin;Paul L. Hermonat;Antonella Ravaggi;Stefania Bellone

  • Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.

    Amanda N. Fader;Dana M. Roque;Eric Siegel;Natalia Buza

  • Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu

    Alessandro D. Santin;Stefania Bellone;Juan J. Roman;Jesse K. McKenney

  • Induction of Human Papillomavirus-Specific CD4+ and CD8+ Lymphocytes by E7-Pulsed Autologous Dendritic Cells in Patients with Human Papillomavirus Type 16- and 18-Positive Cervical Cancer

    Alessandro D. Santin;Paul L. Hermonat;Antonella Ravaggi;Antonella Ravaggi;Maurizio Chiriva-Internati

  • Overexpression of HER-2/neu in uterine serous papillary cancer.

    Alessandro D Santin;Stefania Bellone;Murat Gokden;Michela Palmieri

  • Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation.

    L Yan;J Zhou;Y Gao;S Ghazal

  • HER2 Expression Beyond Breast Cancer: Therapeutic Implications for Gynecologic Malignancies

    Diana P. English;Dana M. Roque;Alessandro D. Santin

  • Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.

    A. Bardia;W.A. Messersmith;E.A. Kio;J.D. Berlin

  • Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition

    Siming Zhao;Stefania Bellone;Salvatore Lopez;Durga Thakral

  • Human Papillomavirus Type 16 and 18 E7-Pulsed Dendritic Cell Vaccination of Stage IB or IIA Cervical Cancer Patients: a Phase I Escalating-Dose Trial

    Alessandro D. Santin;Stefania Bellone;Michela Palmieri;Alessandro Zanolini

  • Regression of Chemotherapy-Resistant Polymerase ε (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab

    Alessandro D. Santin;Stefania Bellone;Natalia Buza;Jungmin Choi

  • A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk

    Elena Ratner;Lingeng Lu;Marta Boeke;Rachel Barnett

Frequent Co-Authors

Peter E. Schwartz
Peter E. Schwartz Yale University
Sergio Pecorelli
Sergio Pecorelli University of Brescia
Martin J. Cannon
Martin J. Cannon University of Arkansas for Medical Sciences
Richard P. Lifton
Richard P. Lifton Rockefeller University
Nicoletta Colombo
Nicoletta Colombo University of Milano-Bicocca
Michael J. Birrer
Michael J. Birrer University of Arkansas for Medical Sciences
Joseph Schlessinger
Joseph Schlessinger Yale University
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Fabio Facchetti
Fabio Facchetti University of Brescia
Lingeng Lu
Lingeng Lu Yale University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Medicine is a dynamic field with a wide range of professional pathways beyond traditional medical school. Aspiring healthcare professionals can advance or specialize through numerous accredited online programs. For registered nurses seeking higher clinical roles, rn to fnp bridge programs offer a flexible way to transition from an Associate Degree in Nursing to a Family Nurse Practitioner role.

Nutrition is another growing area of interest, and earning an online bs in nutrition provides a solid foundation for those looking to impact community health or pursue dietetics careers. For future healthcare leaders, a cahme accredited mha online programs can open doors to hospital administration, policy, or organizational leadership within the healthcare sector.

Nursing professionals wishing to upgrade their qualifications without the need for additional practical experience may consider rn to bsn programs no clinicals, streamlining the path to a Bachelor of Science in Nursing. Each of these online degrees contributes valuable skills and specialized knowledge, supporting diverse and rewarding career paths in modern healthcare.

Best Scientists Citing Alessandro D. Santin

Trending Scientists